TSHA
Taysha Gene Therapies, Inc.
$6.81
+2.10%
2026-05-08
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Key Fundamentals
Forward P/E
-16.38
EPS (TTM)
$-0.38
ROE
-97.3%
Profit Margin
0.0%
Debt/Equity
31.48
Price/Book
7.71
Beta
0.99
Market Cap
$1.92B
Avg Volume (10D)
2.4M
Recent Breakout Signals
No recent breakout signals detected for TSHA.
Recent Price Range (60 Days)
60D High
$7.30
60D Low
$4.03
Avg Volume
2.7M
Latest Close
$6.81
Get breakout alerts for TSHA
Sign up for Breakout Scanner to receive daily notifications when TSHA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Taysha Gene Therapies, Inc. (TSHA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors TSHA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. TSHA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.